<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">35197969</PMID><DateCompleted><Year>2022</Year><Month>03</Month><Day>22</Day></DateCompleted><DateRevised><Year>2022</Year><Month>08</Month><Day>12</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1664-3224</ISSN><JournalIssue CitedMedium="Internet"><Volume>13</Volume><PubDate><Year>2022</Year></PubDate></JournalIssue><Title>Frontiers in immunology</Title><ISOAbbreviation>Front Immunol</ISOAbbreviation></Journal><ArticleTitle>Tofacitinib Suppresses Natural Killer Cells <i>In Vitro</i> and <i>In Vivo</i>: Implications for Amyotrophic Lateral Sclerosis.</ArticleTitle><Pagination><StartPage>773288</StartPage><MedlinePgn>773288</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">773288</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fimmu.2022.773288</ELocationID><Abstract><AbstractText>Amyotrophic lateral sclerosis (ALS) is a fatal and incurable neurodegenerative disease with few therapeutic options. However, the immune system, including natural killer (NK) cells, is linked to ALS progression and may constitute a viable therapeutic ALS target. Tofacitinib is an FDA-approved immunomodulating small molecule which suppresses immune cell function by blocking proinflammatory cytokine signaling. This includes the cytokine IL-15 which is the primary cytokine associated with NK cell function and proliferation. However, the impact of tofacitinib on NK activation and cytotoxicity has not been thoroughly investigated, particularly in ALS. We therefore tested the ability of tofacitinib to suppress cytotoxicity and cytokine production in an NK cell line and in primary NK cells derived from control and ALS participants. We also investigated whether tofacitinib protected ALS neurons from NK cell cytotoxicity. Finally, we conducted a comprehensive pharmacokinetic study of tofacitinib in mice and tested the feasibility of administration formulated in chow. Success was assessed through the impact of tofacitinib on peripheral NK cell levels in mice. We found tofacitinib suppressed IL-15-induced activation as measured by STAT1 phosphorylation, cytotoxicity, pro-inflammatory gene expression, and pro-inflammatory cytokine secretion in both an NK cell line and primary NK cells. Furthermore, tofacitinib protected ALS neurons from NK cell-mediated cytotoxicity. In mice, we found tofacitinib bioavailability was 37% in both male and female mice; using these data we formulated mouse containing low and high doses of tofacitinib and found that the drug suppressed peripheral NK cell levels in a dose-dependent manner. These results demonstrate that tofacitinib can suppress NK cell function and may be a viable therapeutic strategy for ALS.</AbstractText><CopyrightInformation>Copyright &#xa9; 2022 Figueroa-Romero, Monteagudo, Murdock, Famie, Webber-Davis, Piecuch, Teener, Pacut, Goutman and Feldman.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Figueroa-Romero</LastName><ForeName>Claudia</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Michigan, Ann Arbor, MI, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Monteagudo</LastName><ForeName>Alina</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Michigan, Ann Arbor, MI, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Murdock</LastName><ForeName>Benjamin J</ForeName><Initials>BJ</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Michigan, Ann Arbor, MI, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Famie</LastName><ForeName>Joshua P</ForeName><Initials>JP</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Michigan, Ann Arbor, MI, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Webber-Davis</LastName><ForeName>Ian F</ForeName><Initials>IF</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Michigan, Ann Arbor, MI, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Piecuch</LastName><ForeName>Caroline E</ForeName><Initials>CE</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Michigan, Ann Arbor, MI, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Teener</LastName><ForeName>Samuel J</ForeName><Initials>SJ</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Michigan, Ann Arbor, MI, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pacut</LastName><ForeName>Crystal</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Michigan, Ann Arbor, MI, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Goutman</LastName><ForeName>Stephen A</ForeName><Initials>SA</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Michigan, Ann Arbor, MI, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Feldman</LastName><ForeName>Eva L</ForeName><Initials>EL</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Michigan, Ann Arbor, MI, United States.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 TS000289</GrantID><Acronym>TS</Acronym><Agency>ATSDR CDC HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21 NS102960</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K23 ES027221</GrantID><Acronym>ES</Acronym><Agency>NIEHS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 ES030049</GrantID><Acronym>ES</Acronym><Agency>NIEHS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS120926</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>02</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Immunol</MedlineTA><NlmUniqueID>101560960</NlmUniqueID><ISSNLinking>1664-3224</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016207">Cytokines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010880">Piperidines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011743">Pyrimidines</NameOfSubstance></Chemical><Chemical><RegistryNumber>87LA6FU830</RegistryNumber><NameOfSubstance UI="C479163">tofacitinib</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016207" MajorTopicYN="N">Cytokines</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007694" MajorTopicYN="N">Killer Cells, Natural</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019636" MajorTopicYN="N">Neurodegenerative Diseases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010880" MajorTopicYN="N">Piperidines</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011743" MajorTopicYN="N">Pyrimidines</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ALS</Keyword><Keyword MajorTopicYN="N">JAK/STAT</Keyword><Keyword MajorTopicYN="N">NK cells</Keyword><Keyword MajorTopicYN="N">immune system</Keyword><Keyword MajorTopicYN="N">tofacitinib</Keyword></KeywordList><CoiStatement>BM, SG, and EF are listed as inventors on a patent, Issue number US10660895, held by University of Michigan titled &#x201c;Methods for Treating Amyotrophic Lateral Sclerosis&#x201d; that targets immune pathways for use in ALS therapeutics. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>9</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>1</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>2</Month><Day>24</Day><Hour>5</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>2</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>3</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35197969</ArticleId><ArticleId IdType="pmc">PMC8859451</ArticleId><ArticleId IdType="doi">10.3389/fimmu.2022.773288</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Goutman SA. Diagnosis and Clinical Management of Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders. Continuum (Minneap Minn) (2017) 23(5, Peripheral Nerve and Motor Neuron Disorders):1332&#x2013;59. doi: 10.1212/CON.0000000000000535</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/CON.0000000000000535</ArticleId><ArticleId IdType="pubmed">28968365</ArticleId></ArticleIdList></Reference><Reference><Citation>Murdock BJ, Bender DE, Segal BM, Feldman EL. The Dual Roles of Immunity in ALS: Injury Overrides Protection. Neurobiol Dis (2015) 77:1&#x2013;12. doi: 10.1016/j.nbd.2015.02.017</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2015.02.017</ArticleId><ArticleId IdType="pubmed">25726748</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao W, Beers DR, Appel SH. Immune-Mediated Mechanisms in the Pathoprogression of Amyotrophic Lateral Sclerosis. J Neuroimmune Pharmacol Off J Soc NeuroImmune Pharmacol (2013) 8(4):888&#x2013;99. doi: 10.1007/s11481-013-9489-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11481-013-9489-x</ArticleId><ArticleId IdType="pmc">PMC4126425</ArticleId><ArticleId IdType="pubmed">23881705</ArticleId></ArticleIdList></Reference><Reference><Citation>Beers DR, Henkel JS, Zhao W, Wang J, Appel SH. CD4+ T Cells Support Glial Neuroprotection, Slow Disease Progression, and Modify Glial Morphology in an Animal Model of Inherited ALS. Proc Natl Acad Sci USA (2008) 105(40):15558&#x2013;63. doi: 10.1073/pnas.0807419105</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0807419105</ArticleId><ArticleId IdType="pmc">PMC2547419</ArticleId><ArticleId IdType="pubmed">18809917</ArticleId></ArticleIdList></Reference><Reference><Citation>Henkel JS, Beers DR, Siklos L, Appel SH. The Chemokine MCP-1 and the Dendritic and Myeloid Cells it Attracts Are Increased in the Msod1 Mouse Model of ALS. Mol Cell Neurosci (2006) 31(3):427&#x2013;37. doi: 10.1016/j.mcn.2005.10.016</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mcn.2005.10.016</ArticleId><ArticleId IdType="pubmed">16337133</ArticleId></ArticleIdList></Reference><Reference><Citation>Butovsky O, Siddiqui S, Gabriely G, Lanser AJ, Dake B, Murugaiyan G, et al. . Modulating Inflammatory Monocytes With a Unique microRNA Gene Signature Ameliorates Murine ALS. J Clin Invest (2012) 122(9):3063&#x2013;87. doi: 10.1172/JCI62636</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI62636</ArticleId><ArticleId IdType="pmc">PMC3428086</ArticleId><ArticleId IdType="pubmed">22863620</ArticleId></ArticleIdList></Reference><Reference><Citation>Garofalo S, Cocozza G, Porzia A, Inghilleri M, Raspa M, Scavizzi F, et al. . Natural Killer Cells Modulate Motor Neuron-Immune Cell Cross Talk in Models of Amyotrophic Lateral Sclerosis. Nat Commun (2020) 11(1):1773. doi: 10.1038/s41467-020-15644-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-020-15644-8</ArticleId><ArticleId IdType="pmc">PMC7156729</ArticleId><ArticleId IdType="pubmed">32286313</ArticleId></ArticleIdList></Reference><Reference><Citation>Finkelstein A, Kunis G, Seksenyan A, Ronen A, Berkutzki T, Azoulay D, et al. . Abnormal Changes in NKT Cells, the IGF-1 Axis, and Liver Pathology in an Animal Model of ALS. PloS One (2011) 6(8):e22374. doi: 10.1371/journal.pone.0022374</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0022374</ArticleId><ArticleId IdType="pmc">PMC3149057</ArticleId><ArticleId IdType="pubmed">21829620</ArticleId></ArticleIdList></Reference><Reference><Citation>Figueroa-Romero C, Guo K, Murdock BJ, Paez-Colasante X, Bassis CM, Mikhail KA, et al. . Temporal Evolution of the Microbiome, Immune System and Epigenome With Disease Progression in ALS Mice. Dis Models Mech (2019) 13(2). doi: 10.1242/dmm.041947</Citation><ArticleIdList><ArticleId IdType="doi">10.1242/dmm.041947</ArticleId><ArticleId IdType="pmc">PMC6906635</ArticleId><ArticleId IdType="pubmed">31597644</ArticleId></ArticleIdList></Reference><Reference><Citation>Murdock BJ, Zhou T, Kashlan SR, Little RJ, Goutman SA, Feldman EL. Correlation of Peripheral Immunity With Rapid Amyotrophic Lateral Sclerosis Progression. JAMA Neurol (2017) 74(12):1446&#x2013;54. doi: 10.1001/jamaneurol.2017.2255</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2017.2255</ArticleId><ArticleId IdType="pmc">PMC5822195</ArticleId><ArticleId IdType="pubmed">28973548</ArticleId></ArticleIdList></Reference><Reference><Citation>Gustafson MP, Staff NP, Bornschlegl S, Butler GW, Maas ML, Kazamel M, et al. . Comprehensive Immune Profiling Reveals Substantial Immune System Alterations in a Subset of Patients With Amyotrophic Lateral Sclerosis. PloS One (2017) 12(7):e0182002. doi: 10.1371/journal.pone.0182002</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0182002</ArticleId><ArticleId IdType="pmc">PMC5526569</ArticleId><ArticleId IdType="pubmed">28742871</ArticleId></ArticleIdList></Reference><Reference><Citation>Murdock BJ, Goutman SA, Boss J, Kim S, Feldman EL. Amyotrophic Lateral Sclerosis Survival Associates With Neutrophils in a Sex-Specific Manner. Neurology(R) Neuroimmunol Neuroinflamm (2021) 8(2). doi: 10.1212/NXI.0000000000000953</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/NXI.0000000000000953</ArticleId><ArticleId IdType="pmc">PMC8057067</ArticleId><ArticleId IdType="pubmed">33531377</ArticleId></ArticleIdList></Reference><Reference><Citation>Murdock BJ, Famie JP, Piecuch CE, Raue KD, Mendelson FE, Pieroni CH, et al. . Natural Killer Cells Associate With Amyotrophic Lateral Sclersois in a Sex- and Age-Dependent Manner. JCI Insight (2021) 6(11). doi: 10.1172/jci.insight.147129</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/jci.insight.147129</ArticleId><ArticleId IdType="pmc">PMC8262328</ArticleId><ArticleId IdType="pubmed">33974561</ArticleId></ArticleIdList></Reference><Reference><Citation>Penn I. Cancer is a Complication of Severe Immunosuppression. Surg Gynecol Obstet (1986) 162(6):603&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="pubmed">3520906</ArticleId></ArticleIdList></Reference><Reference><Citation>Gordon PH, Moore DH, Miller RG, Florence JM, Verheijde JL, Doorish C, et al. . Efficacy of Minocycline in Patients With Amyotrophic Lateral Sclerosis: A Phase III Randomised Trial. Lancet Neurol (2007) 6(12):1045&#x2013;53. doi: 10.1016/S1474-4422(07)70270-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(07)70270-3</ArticleId><ArticleId IdType="pubmed">17980667</ArticleId></ArticleIdList></Reference><Reference><Citation>Meininger V, Asselain B, Guillet P, Leigh PN, Ludolph A, Lacomblez L, et al. . Pentoxifylline in ALS: A Double-Blind, Randomized, Multicenter, Placebo-Controlled Trial. Neurology (2006) 66(1):88&#x2013;92. doi: 10.1212/01.wnl.0000191326.40772.62</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.wnl.0000191326.40772.62</ArticleId><ArticleId IdType="pubmed">16401852</ArticleId></ArticleIdList></Reference><Reference><Citation>Vivier E, Tomasello E, Baratin M, Walzer T, Ugolini S. Functions of Natural Killer Cells. Nat Immunol (2008) 9(5):503&#x2013;10. doi: 10.1038/ni1582</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ni1582</ArticleId><ArticleId IdType="pubmed">18425107</ArticleId></ArticleIdList></Reference><Reference><Citation>Davies AJ, Kim HW, Gonzalez-Cano R, Choi J, Back SK, Roh SE, et al. . Natural Killer Cells Degenerate Intact Sensory Afferents Following Nerve Injury. Cell (2019) 176(4):716&#x2013;28.e18. doi: 10.1016/j.cell.2018.12.022</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2018.12.022</ArticleId><ArticleId IdType="pmc">PMC6418410</ArticleId><ArticleId IdType="pubmed">30712871</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiu IM, Chen A, Zheng Y, Kosaras B, Tsiftsoglou SA, Vartanian TK, et al. . T Lymphocytes Potentiate Endogenous Neuroprotective Inflammation in a Mouse Model of ALS. Proc Natl Acad Sci USA (2008) 105(46):17913&#x2013;8. doi: 10.1073/pnas.0804610105</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0804610105</ArticleId><ArticleId IdType="pmc">PMC2581614</ArticleId><ArticleId IdType="pubmed">18997009</ArticleId></ArticleIdList></Reference><Reference><Citation>Song S, Miranda CJ, Braun L, Meyer K, Frakes AE, Ferraiuolo L, et al. . Major Histocompatibility Complex Class I Molecules Protect Motor Neurons From Astrocyte-Induced Toxicity in Amyotrophic Lateral Sclerosis. Nat Med (2016) 22(4):397&#x2013;403. doi: 10.1038/nm.4052</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm.4052</ArticleId><ArticleId IdType="pmc">PMC4823173</ArticleId><ArticleId IdType="pubmed">26928464</ArticleId></ArticleIdList></Reference><Reference><Citation>Borrego F, Kabat J, Kim DK, Lieto L, Maasho K, Pena J, et al. . Structure and Function of Major Histocompatibility Complex (MHC) Class I Specific Receptors Expressed on Human Natural Killer (NK) Cells. Mol Immunol (2002) 38(9):637&#x2013;60. doi: 10.1016/S0161-5890(01)00107-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0161-5890(01)00107-9</ArticleId><ArticleId IdType="pubmed">11858820</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee EB, Fleischmann R, Hall S, Wilkinson B, Bradley JD, Gruben D, et al. . Tofacitinib Versus Methotrexate in Rheumatoid Arthritis. N Engl J Med (2014) 370(25):2377&#x2013;86. doi: 10.1056/NEJMoa1310476</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1310476</ArticleId><ArticleId IdType="pubmed">24941177</ArticleId></ArticleIdList></Reference><Reference><Citation>Sandborn WJ, Su C, Sands BE, D'Haens GR, Vermeire S, Schreiber S, et al. . Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis. N Engl J Med (2017) 376(18):1723&#x2013;36. doi: 10.1056/NEJMoa1606910</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1606910</ArticleId><ArticleId IdType="pubmed">28467869</ArticleId></ArticleIdList></Reference><Reference><Citation>Gladman D, Rigby W, Azevedo VF, Behrens F, Blanco R, Kaszuba A, et al. . Tofacitinib for Psoriatic Arthritis in Patients With an Inadequate Response to TNF Inhibitors. N Engl J Med (2017) 377(16):1525&#x2013;36. doi: 10.1056/NEJMoa1615977</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1615977</ArticleId><ArticleId IdType="pubmed">29045207</ArticleId></ArticleIdList></Reference><Reference><Citation>Flanagan ME, Blumenkopf TA, Brissette WH, Brown MF, Casavant JM, Shang-Poa C, et al. . Discovery of CP-690,550: A Potent and Selective Janus Kinase (JAK) Inhibitor for the Treatment of Autoimmune Diseases and Organ Transplant Rejection. J Med Chem (2010) 53(24):8468&#x2013;84. doi: 10.1021/jm1004286</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/jm1004286</ArticleId><ArticleId IdType="pubmed">21105711</ArticleId></ArticleIdList></Reference><Reference><Citation>Hodge JA, Kawabata TT, Krishnaswami S, Clark JD, Telliez JB, Dowty ME, et al. . The Mechanism of Action of Tofacitinib - An Oral Janus Kinase Inhibitor for the Treatment of Rheumatoid Arthritis. Clin Exp Rheumatol (2016) 34(2):318&#x2013;28.</Citation><ArticleIdList><ArticleId IdType="pubmed">26966791</ArticleId></ArticleIdList></Reference><Reference><Citation>Sonomoto K, Yamaoka K, Kubo S, Hirata S, Fukuyo S, Maeshima K, et al. . Effects of Tofacitinib on Lymphocytes in Rheumatoid Arthritis: Relation to Efficacy and Infectious Adverse Events. Rheumatology (2014) 53(5):914&#x2013;8. doi: 10.1093/rheumatology/ket466</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/ket466</ArticleId><ArticleId IdType="pubmed">24441153</ArticleId></ArticleIdList></Reference><Reference><Citation>Sewgobind VD, Quaedackers ME, van der Laan LJ, Kraaijeveld R, Korevaar SS, Chan G, et al. . The Jak Inhibitor CP-690,550 Preserves the Function of CD4CD25FoxP3 Regulatory T Cells and Inhibits Effector T Cells. Am J Transplant Off J Am Soc Transplant Am Soc Transplant Surgeons (2010) 10(8):1785&#x2013;95. doi: 10.1111/j.1600-6143.2010.03200.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1600-6143.2010.03200.x</ArticleId><ArticleId IdType="pubmed">20626385</ArticleId></ArticleIdList></Reference><Reference><Citation>Strowig T, Chijioke O, Carrega P, Arrey F, Meixlsperger S, Ramer PC, et al. . Human NK Cells of Mice With Reconstituted Human Immune System Components Require Preactivation to Acquire Functional Competence. Blood (2010) 116(20):4158&#x2013;67. doi: 10.1182/blood-2010-02-270678</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2010-02-270678</ArticleId><ArticleId IdType="pmc">PMC2993621</ArticleId><ArticleId IdType="pubmed">20671122</ArticleId></ArticleIdList></Reference><Reference><Citation>Fehniger TA, Shah MH, Turner MJ, VanDeusen JB, Whitman SP, Cooper MA, et al. . Differential Cytokine and Chemokine Gene Expression by Human NK Cells Following Activation With IL-18 or IL-15 in Combination With IL-12: Implications for the Innate Immune Response. J Immunol (1999) 162(8):4511&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pubmed">10201989</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi SS, Chhabra VS, Nguyen QH, Ank BJ, Stiehm ER, Roberts RL. Interleukin-15 Enhances Cytotoxicity, Receptor Expression, and Expansion of Neonatal Natural Killer Cells in Long-Term Culture. Clin Diagn Lab Immunol (2004) 11(5):879&#x2013;88. doi: 10.1128/CDLI.11.5.879-888.2004</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/CDLI.11.5.879-888.2004</ArticleId><ArticleId IdType="pmc">PMC515280</ArticleId><ArticleId IdType="pubmed">15358647</ArticleId></ArticleIdList></Reference><Reference><Citation>Allavena P, Giardina G, Bianchi G, Mantovani A. IL-15 is Chemotactic for Natural Killer Cells and Stimulates Their Adhesion to Vascular Endothelium. J Leukocyte Biol (1997) 61(6):729&#x2013;35. doi: 10.1002/jlb.61.6.729</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jlb.61.6.729</ArticleId><ArticleId IdType="pubmed">9201264</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnston JA, Bacon CM, Finbloom DS, Rees RC, Kaplan D, Shibuya K, et al. . Tyrosine Phosphorylation and Activation of STAT5, STAT3, and Janus Kinases by Interleukins 2 and 15. Proc Natl Acad Sci USA (1995) 92(19):8705&#x2013;9. doi: 10.1073/pnas.92.19.8705</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.92.19.8705</ArticleId><ArticleId IdType="pmc">PMC41035</ArticleId><ArticleId IdType="pubmed">7568001</ArticleId></ArticleIdList></Reference><Reference><Citation>Shimaoka H, Takeno S, Maki K, Sasaki T, Hasegawa S, Yamashita Y. A Cytokine Signal Inhibitor for Rheumatoid Arthritis Enhances Cancer Metastasis via Depletion of NK Cells in an Experimental Lung Metastasis Mouse Model of Colon Cancer. Oncol Lett (2017) 14(3):3019&#x2013;27. doi: 10.3892/ol.2017.6473</Citation><ArticleIdList><ArticleId IdType="doi">10.3892/ol.2017.6473</ArticleId><ArticleId IdType="pmc">PMC5588136</ArticleId><ArticleId IdType="pubmed">28928840</ArticleId></ArticleIdList></Reference><Reference><Citation>Llop-Guevara A, Porras M, Cendon C, Di Ceglie I, Siracusa F, Madarena F, et al. . Simultaneous Inhibition of JAK and SYK Kinases Ameliorates Chronic and Destructive Arthritis in Mice. Arthritis Res Ther (2015) 17:356. doi: 10.1186/s13075-015-0866-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13075-015-0866-0</ArticleId><ArticleId IdType="pmc">PMC4675041</ArticleId><ArticleId IdType="pubmed">26653844</ArticleId></ArticleIdList></Reference><Reference><Citation>van Gurp E, Weimar W, Gaston R, Brennan D, Mendez R, Pirsch J, et al. . Phase 1 Dose-Escalation Study of CP-690 550 in Stable Renal Allograft Recipients: Preliminary Findings of Safety, Tolerability, Effects on Lymphocyte Subsets and Pharmacokinetics. Am J Transplant Off J Am Soc Transplant Am Soc Transplant Surgeons (2008) 8(8):1711&#x2013;8. doi: 10.1111/j.1600-6143.2008.02307.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1600-6143.2008.02307.x</ArticleId><ArticleId IdType="pubmed">18557720</ArticleId></ArticleIdList></Reference><Reference><Citation>Hooten KG, Beers DR, Zhao W, Appel SH. Protective and Toxic Neuroinflammation in Amyotrophic Lateral Sclerosis. Neurother J Am Soc Exp Neurother (2015) 12(2):364&#x2013;75. doi: 10.1007/s13311-014-0329-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13311-014-0329-3</ArticleId><ArticleId IdType="pmc">PMC4404435</ArticleId><ArticleId IdType="pubmed">25567201</ArticleId></ArticleIdList></Reference><Reference><Citation>Tank EM, Figueroa-Romero C, Hinder LM, Bedi K, Archbold HC, Li X, et al. . Abnormal RNA Stability in Amyotrophic Lateral Sclerosis. Nat Commun (2018) 9(1):2845. doi: 10.1038/s41467-018-05049-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-018-05049-z</ArticleId><ArticleId IdType="pmc">PMC6054632</ArticleId><ArticleId IdType="pubmed">30030424</ArticleId></ArticleIdList></Reference><Reference><Citation>Xue Y, Ouyang K, Huang J, Zhou Y, Ouyang H, Li H, et al. . Direct Conversion of Fibroblasts to Neurons by Reprogramming PTB-Regulated microRNA Circuits. Cell (2013) 152(1-2):82&#x2013;96. doi: 10.1016/j.cell.2012.11.045</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2012.11.045</ArticleId><ArticleId IdType="pmc">PMC3552026</ArticleId><ArticleId IdType="pubmed">23313552</ArticleId></ArticleIdList></Reference><Reference><Citation>Dowty ME, Jesson MI, Ghosh S, Lee J, Meyer DM, Krishnaswami S, et al. . Preclinical to Clinical Translation of Tofacitinib, a Janus Kinase Inhibitor, in Rheumatoid Arthritis. J Pharmacol Exp Ther (2014) 348(1):165&#x2013;73. doi: 10.1124/jpet.113.209304</Citation><ArticleIdList><ArticleId IdType="doi">10.1124/jpet.113.209304</ArticleId><ArticleId IdType="pubmed">24218541</ArticleId></ArticleIdList></Reference><Reference><Citation>Nocturne G, Pascaud J, Ly B, Tahmasebi F, Mariette X. JAK Inhibitors Alter NK Cell Functions and May Impair Immunosurveillance Against Lymphomagenesis. Cell Mol Immunol (2020) 17(5):552&#x2013;3. doi: 10.1038/s41423-019-0320-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41423-019-0320-3</ArticleId><ArticleId IdType="pmc">PMC7193549</ArticleId><ArticleId IdType="pubmed">31664224</ArticleId></ArticleIdList></Reference><Reference><Citation>Bryceson YT, March ME, Ljunggren HG, Long EO. Synergy Among Receptors on Resting NK Cells for the Activation of Natural Cytotoxicity and Cytokine Secretion. Blood (2006) 107(1):159&#x2013;66. doi: 10.1182/blood-2005-04-1351</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2005-04-1351</ArticleId><ArticleId IdType="pmc">PMC1895346</ArticleId><ArticleId IdType="pubmed">16150947</ArticleId></ArticleIdList></Reference><Reference><Citation>Diaz-Hernandez JI, Moncada S, Bolanos JP, Almeida A. Poly(ADP-Ribose) Polymerase-1 Protects Neurons Against Apoptosis Induced by Oxidative Stress. Cell Death Differ (2007) 14(6):1211&#x2013;21. doi: 10.1038/sj.cdd.4402117</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.cdd.4402117</ArticleId><ArticleId IdType="pubmed">17347665</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaz AR, Delgado-Esteban M, Brito MA, Bolanos JP, Brites D, Almeida A. Bilirubin Selectively Inhibits Cytochrome C Oxidase Activity and Induces Apoptosis in Immature Cortical Neurons: Assessment of the Protective Effects of Glycoursodeoxycholic Acid. J Neurochem (2010) 112(1):56&#x2013;65. doi: 10.1111/j.1471-4159.2009.06429.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1471-4159.2009.06429.x</ArticleId><ArticleId IdType="pubmed">19818102</ArticleId></ArticleIdList></Reference><Reference><Citation>Razali NM, Wah YB. Power Comparisons of Shapiro-Wilk, Kolmogorov-Smirnov, Lilliefors and Anderson-Darling Tests. J Stat Mod Anal (2011) 2(1):21&#x2013;33.</Citation></Reference><Reference><Citation>van Vollenhoven R, Lee EB, Strengholt S, Mojcik C, Valdez H, Krishnaswami S, et al. . Evaluation of the Short-, Mid-, and Long-Term Effects of Tofacitinib on Lymphocytes in Patients With Rheumatoid Arthritis. Arthritis Rheumatol (2019) 71(5):685&#x2013;95. doi: 10.1002/art.40780</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.40780</ArticleId><ArticleId IdType="pmc">PMC6593802</ArticleId><ArticleId IdType="pubmed">30427585</ArticleId></ArticleIdList></Reference><Reference><Citation>Murray PJ. The JAK-STAT Signaling Pathway: Input and Output Integration. J Immunol (2007) 178(5):2623&#x2013;9. doi: 10.4049/jimmunol.178.5.2623</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.178.5.2623</ArticleId><ArticleId IdType="pubmed">17312100</ArticleId></ArticleIdList></Reference><Reference><Citation>Alter G, Malenfant JM, Altfeld M. CD107a as a Functional Marker for the Identification of Natural Killer Cell Activity. J Immunol Methods (2004) 294(1-2):15&#x2013;22. doi: 10.1016/j.jim.2004.08.008</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jim.2004.08.008</ArticleId><ArticleId IdType="pubmed">15604012</ArticleId></ArticleIdList></Reference><Reference><Citation>Voskoboinik I, Smyth MJ, Trapani JA. Perforin-Mediated Target-Cell Death and Immune Homeostasis. Nat Rev Immunol (2006) 6(12):940&#x2013;52. doi: 10.1038/nri1983</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nri1983</ArticleId><ArticleId IdType="pubmed">17124515</ArticleId></ArticleIdList></Reference><Reference><Citation>Weskamp K, Tank EM, Miguez R, McBride JP, Gomez NB, White M, et al. . Shortened TDP43 Isoforms Upregulated by Neuronal Hyperactivity Drive TDP43 Pathology in ALS. J Clin Invest (2020) 130(3):1139&#x2013;55. doi: 10.1101/648477</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/648477</ArticleId><ArticleId IdType="pmc">PMC7269575</ArticleId><ArticleId IdType="pubmed">31714900</ArticleId></ArticleIdList></Reference><Reference><Citation>Milici AJ, Kudlacz EM, Audoly L, Zwillich S, Changelian P. Cartilage Preservation by Inhibition of Janus Kinase 3 in Two Rodent Models of Rheumatoid Arthritis. Arthritis Res Ther (2008) 10(1):R14. doi: 10.1186/ar2365</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/ar2365</ArticleId><ArticleId IdType="pmc">PMC2374467</ArticleId><ArticleId IdType="pubmed">18234077</ArticleId></ArticleIdList></Reference><Reference><Citation>Arantes-Rodrigues R, Henriques A, Pinto-Leite R, Faustino-Rocha A, Pinho-Oliveira J, Teixeira-Guedes C, et al. . The Effects of Repeated Oral Gavage on the Health of Male CD-1 Mice. Lab Anim (2012) 41(5):129&#x2013;34. doi: 10.1038/laban0512-129</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/laban0512-129</ArticleId><ArticleId IdType="pubmed">22517091</ArticleId></ArticleIdList></Reference><Reference><Citation>Cocozza G, di Castro MA, Carbonari L, Grimaldi A, Antonangeli F, Garofalo S, et al. . Ca(2+)-Activated K(+) Channels Modulate Microglia Affecting Motor Neuron Survival in Hsod1(G93A) Mice. Brain Behavior Immun (2018) 73:584&#x2013;95. doi: 10.1016/j.bbi.2018.07.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbi.2018.07.002</ArticleId><ArticleId IdType="pmc">PMC6129409</ArticleId><ArticleId IdType="pubmed">29981425</ArticleId></ArticleIdList></Reference><Reference><Citation>Boyle DL, Soma K, Hodge J, Kavanaugh A, Mandel D, Mease P, et al. . The JAK Inhibitor Tofacitinib Suppresses Synovial JAK1-STAT Signalling in Rheumatoid Arthritis. Ann Rheum Dis (2015) 74(6):1311&#x2013;6. doi: 10.1136/annrheumdis-2014-206028</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2014-206028</ArticleId><ArticleId IdType="pmc">PMC4431345</ArticleId><ArticleId IdType="pubmed">25398374</ArticleId></ArticleIdList></Reference><Reference><Citation>Gertel S, Mahagna H, Karmon G, Watad A, Amital H. Tofacitinib Attenuates Arthritis Manifestations and Reduces the Pathogenic CD4 T Cells in Adjuvant Arthritis Rats. Clin Immunol (Orlando Fla) (2017) 184:77&#x2013;81. doi: 10.1016/j.clim.2017.04.015</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clim.2017.04.015</ArticleId><ArticleId IdType="pubmed">28461107</ArticleId></ArticleIdList></Reference><Reference><Citation>Lebrec H, Horner MJ, Gorski KS, Tsuji W, Xia D, Pan WJ, et al. . Homeostasis of Human NK Cells is Not IL-15 Dependent. J Immunol (2013) 191(11):5551&#x2013;8. doi: 10.4049/jimmunol.1301000</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.1301000</ArticleId><ArticleId IdType="pubmed">24184554</ArticleId></ArticleIdList></Reference><Reference><Citation>Koka R, Burkett P, Chien M, Chai S, Boone DL, Ma A. Cutting Edge: Murine Dendritic Cells Require IL-15R Alpha to Prime NK Cells. J Immunol (2004) 173(6):3594&#x2013;8. doi: 10.4049/jimmunol.173.6.3594</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.173.6.3594</ArticleId><ArticleId IdType="pubmed">15356102</ArticleId></ArticleIdList></Reference><Reference><Citation>Gupta PS, Stock TC, Wang R, Alvey C, Choo HW, Krishnaswami S. A Phase 1 Study to Estimate the Absolute Oral Bioavailability of Tofacitinib (CP-690,550) in Healthy Subjects (Abstract 1122902). J Clin Pharmacol (2011) 51(9):1348.</Citation></Reference><Reference><Citation>Lee JS, Kim SH. Dose-Dependent Pharmacokinetics of Tofacitinib in Rats: Influence of Hepatic and Intestinal First-Pass Metabolism. Pharmaceutics (2019) 11(7). doi: 10.3390/pharmaceutics11070318</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/pharmaceutics11070318</ArticleId><ArticleId IdType="pmc">PMC6681021</ArticleId><ArticleId IdType="pubmed">31284540</ArticleId></ArticleIdList></Reference><Reference><Citation>Beers DR, Henkel JS, Xiao Q, Zhao W, Wang J, Yen AA, et al. . Wild-Type Microglia Extend Survival in PU.1 Knockout Mice With Familial Amyotrophic Lateral Sclerosis. Proc Natl Acad Sci USA (2006) 103(43):16021&#x2013;6. doi: 10.1073/pnas.0607423103</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0607423103</ArticleId><ArticleId IdType="pmc">PMC1613228</ArticleId><ArticleId IdType="pubmed">17043238</ArticleId></ArticleIdList></Reference><Reference><Citation>Henkel JS, Engelhardt JI, Siklos L, Simpson EP, Kim SH, Pan T, et al. . Presence of Dendritic Cells, MCP-1, and Activated Microglia/Macrophages in Amyotrophic Lateral Sclerosis Spinal Cord Tissue. Ann Neurol (2004) 55(2):221&#x2013;35. doi: 10.1002/ana.10805</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.10805</ArticleId><ArticleId IdType="pubmed">14755726</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao W, Beers DR, Henkel JS, Zhang W, Urushitani M, Julien JP, et al. . Extracellular Mutant SOD1 Induces Microglial-Mediated Motoneuron Injury. Glia (2010) 58(2):231&#x2013;43. doi: 10.1002/glia.20919</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/glia.20919</ArticleId><ArticleId IdType="pmc">PMC2784168</ArticleId><ArticleId IdType="pubmed">19672969</ArticleId></ArticleIdList></Reference><Reference><Citation>Nardo G, Trolese MC, Bendotti C. Major Histocompatibility Complex I Expression by Motor Neurons and Its Implication in Amyotrophic Lateral Sclerosis. Front Neurol (2016) 7:89. doi: 10.3389/fneur.2016.00089</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2016.00089</ArticleId><ArticleId IdType="pmc">PMC4904147</ArticleId><ArticleId IdType="pubmed">27379008</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang J, Zhang L, Yu C, Yang XF, Wang H. Monocyte and Macrophage Differentiation: Circulation Inflammatory Monocyte as Biomarker for Inflammatory Diseases. Biomark Res (2014) 2(1):1. doi: 10.1186/2050-7771-2-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/2050-7771-2-1</ArticleId><ArticleId IdType="pmc">PMC3892095</ArticleId><ArticleId IdType="pubmed">24398220</ArticleId></ArticleIdList></Reference><Reference><Citation>Zondler L, Muller K, Khalaji S, Bliederhauser C, Ruf WP, Grozdanov V, et al. . Peripheral Monocytes are Functionally Altered and Invade the CNS in ALS Patients. Acta Neuropatholog (2016) 132(3):391&#x2013;411. doi: 10.1007/s00401-016-1548-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-016-1548-y</ArticleId><ArticleId IdType="pubmed">26910103</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y, Wallace DL, de Lara CM, Ghattas H, Asquith B, Worth A, et al. . In Vivo Kinetics of Human Natural Killer Cells: The Effects of Ageing and Acute and Chronic Viral Infection. Immunology (2007) 121(2):258&#x2013;65. doi: 10.1111/j.1365-2567.2007.02573.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2567.2007.02573.x</ArticleId><ArticleId IdType="pmc">PMC2265941</ArticleId><ArticleId IdType="pubmed">17346281</ArticleId></ArticleIdList></Reference><Reference><Citation>Jamieson AM, Isnard P, Dorfman JR, Coles MC, Raulet DH. Turnover and Proliferation of NK Cells in Steady State and Lymphopenic Conditions. J Immunol (2004) 172(2):864&#x2013;70. doi: 10.4049/jimmunol.172.2.864</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.172.2.864</ArticleId><ArticleId IdType="pubmed">14707057</ArticleId></ArticleIdList></Reference><Reference><Citation>Lutz CT, Karapetyan A, Al-Attar A, Shelton BJ, Holt KJ, Tucker JH, et al. . Human NK Cells Proliferate and Die In Vivo More Rapidly Than T Cells in Healthy Young and Elderly Adults. J Immunol (2011) 186(8):4590&#x2013;8. doi: 10.4049/jimmunol.1002732</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.1002732</ArticleId><ArticleId IdType="pmc">PMC3071442</ArticleId><ArticleId IdType="pubmed">21402893</ArticleId></ArticleIdList></Reference><Reference><Citation>Michie CA, McLean A, Alcock C, Beverley PC. Lifespan of Human Lymphocyte Subsets Defined by CD45 Isoforms. Nature (1992) 360(6401):264&#x2013;5. doi: 10.1038/360264a0</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/360264a0</ArticleId><ArticleId IdType="pubmed">1436108</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>